Promomed

Main

News

Main
All news
Mass media
Reports
Press service

All sources

Corporate

For investors

Production

Medicinal preparations

Industry development

Education

All years

2024

2023

2022

2021

2020

December

2December

PROMOMED’s Velgia®: a novel Russian semaglutide product is already available in pharmacies, and its treatment course is by one third more affordable compared to competitor brands

Corporate
For investors
Production
Medicinal preparations
Industry development

November

26November

PROMOMED invests in school education: an online curriculum “Biochemist” was launched for the schoolchildren in Mordovia

Corporate
Production
Education

November

14November

PROMOMED and the Russian Society of Clinical Oncology will join their efforts against cancer

Corporate
For investors
Production
Medicinal preparations
Industry development

November

5November

The Federal Ant-Monopoly Service has endorsed the price of PROMOMED’s new medicine

Corporate
For investors
Production
Medicinal preparations
Industry development

October

28October

The manufacturing of an essential medicine Rivaroxaban, reducing the risk of blood clotting, has been fully localized in Russia

Corporate
Production
Medicinal preparations
Industry development

September

6September

Modelax®-Н won the Smartpharma® Awards prize

Corporate
For investors
Medicinal preparations

September

3September

“ARTCELLENCE”, a biotechnological company, is on the track towards creating cancer vaccines

Corporate
For investors
Medicinal preparations

June

20June

Promomed Group produced the first batch of nilotinib substance

Corporate
Production
Medicinal preparations

June

17June

Promomed Group received the award "For a high-tech project" from RSPP

Corporate
Production
Medicinal preparations

June

11June

Biopharmaceutical industry as a "new IT" for the Russian stock market

For investors
Production
Medicinal preparations

For investors

Information disclosure

Contacts

Menu

For investors

News

December

PROMOMED’s Velgia®: a novel Russian semaglutide product is already available in pharmacies, and its treatment course is by one third more affordable compared to competitor brands

November

PROMOMED invests in school education: an online curriculum “Biochemist” was launched for the schoolchildren in Mordovia

November

PROMOMED and the Russian Society of Clinical Oncology will join their efforts against cancer

November

The Federal Ant-Monopoly Service has endorsed the price of PROMOMED’s new medicine

October

The manufacturing of an essential medicine Rivaroxaban, reducing the risk of blood clotting, has been fully localized in Russia

September

Modelax®-Н won the Smartpharma® Awards prize

September

“ARTCELLENCE”, a biotechnological company, is on the track towards creating cancer vaccines

June

Promomed Group produced the first batch of nilotinib substance

June

Promomed Group received the award "For a high-tech project" from RSPP

June

Biopharmaceutical industry as a "new IT" for the Russian stock market

For investors

Products

Pharmacovigilance